



# Poster 155: Safety and Efficacy of OnabotulinumtoxinA Injections in Octo and Nonagenarians

Patricia M. Zahner<sup>2</sup>, Laura L. Giusto<sup>2</sup>, Jessica Lloyd<sup>2</sup>, Juan C. Guzman<sup>2</sup>, Shree Agrawal<sup>1</sup>, Courtenay K. Moore<sup>2</sup>, Raymond R. Rackley<sup>2</sup>, Sandip P. Vasavada<sup>2</sup>, Howard B. Goldman<sup>2</sup>

<sup>1</sup>Cleveland Clinic Lerner College of Medicine, Case Western Reserve University  
<sup>2</sup>Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic

## BACKGROUND/RATIONALE

- OnabotulinumtoxinA (BTX-A) injections are commonly used third line therapies for treatment of overactive bladder (OAB)
- Urinary tract infections (UTIs) and urinary retention may deter some providers from performing this treatment in the elderly
- This study aims to examine the rate of complications and efficacy in patients 80 years or older versus patients between 50-70 years receiving BTX-A for the treatment of OAB

## METHODS

- Retrospective case series of patients who underwent BTX-A injections at a tertiary care center from January 2007- September 2017
- Patients were stratified to an “elderly” cohort (>80 years old) and a comparator “younger” cohort (50-70 years old)
- Demographics, clinical characteristics, post BTX-A complications and patient reported satisfaction following treatment were collected
- Chi-square and t-tests for patient characteristics and univariable and multivariable logistic regression models were collected for outcomes

## RESULTS

### PATIENT DEMOGRAPHICS

	Young Cohort (50-70 yrs)	Elderly Cohort (>80 yrs)	p-value
<b>Mean Age (years)</b>	59 (50-70)	84 (80-94)	
<b>Number of Patients</b>	68	62	
<b>Co-morbid conditions</b>	65%	76%	0.24
<b>Neurological Condition</b>	53%	29%	0.006

### RESULTS

Complications (%)	Young Cohort (50-70 yrs)	Elderly Cohort (>80 yrs)	p-value
<b>Overall Rate</b>	16	23	0.36
<b>UTI</b>	7.6	6.5	0.84
<b>Hematuria</b>	4.4	1.6	0.36
<b>Unscheduled Phone Calls</b>	10	17	0.22
<b>Unscheduled Office Visits</b>	2.9	6.5	0.34
<b>Pain</b>	5.1	0	0.73
<b>Urinary Retention</b>	4	11	0.14
<b>Rehospitalization</b>	0	3.2	0.14

- 3 patients in YC (4.4%) had urinary retention after BTX-A.  
 - All had a prior incontinence surgery
- 14 patients in the YC had an incontinence procedure, 3 required CIC (21%), compared to 0/54 patients who did not have an incontinence procedure (p = 0.005)
- 7 patients in the EC (11%) had urinary retention after BTX-A

## CONCLUSIONS

- Our data suggest that intradetrusor BTX-A injections are safe and effective in the elderly population
- No significant difference in UTI rate or urinary retention between the two groups